Gilead Sciences Inc (GILD) - Stock Report

The business case is not a simple pipeline story. HIV is the economic spine, Biktarvy remains the cash anchor, and lenacapavir-based prevention and treatment extensions are the bridge that can lengthen the franchise before patent-cycle pressure becomes more important. Oncology and inflammation matter because they can diversify the profit pool, but they must convert clinical and acquired assets into durable cash rather than merely absorbing the HIV engine's surplus.

Q1 2026 was supportive, but it should not be annualized mechanically because the quarter benefited from product mix, lower Veklury drag, and comparison against a prior period with heavier acquired-IPR&D expense. Total revenue rose 4% to $7.0 billion, product sales excluding Veklury rose 8% to $6.8 billion, and HIV product sales rose 10% to $5.0 billion. Biktarvy sales rose 7% to $3.4 billion, Descovy rose 38% to $807 million, and Trodelvy rose 37% to $402 million, while Cell Therapy fell 12% to $407 million. Reported operating margin improved to 37.2%, adjusted operating margin was 46.9%, and operating cash flow was $2.5 billion. That cash signal for the quarter covered $117 million of property and equipment purchases, $1.0 billion of dividends, and $419 million of buybacks; it did not cover the separate $2.8 billion debt repayment and it preceded the late-April Arcellx cash outlay.

The key macro issue is not HIV demand in isolation, but whether Gilead’s HIV cash franchise — led by Biktarvy and lenacapavir — keeps converting through gross and operating margin into post-capex free cash flow per share; if that cash pool stays durable through payer rebates, Medicare Part D redesign, IRA negotiation and patent-cycle pressure, it can keep funding the dividend, debt service and the oncology and inflammation pipeline, while erosion before Trodelvy, Livdelzi and cell therapy become real replacement earnings would leave the valuation ahead of the cash proof.

Gilead is a commercial-stage biopharmaceutical company built around branded therapies for HIV, liver disease, oncology, cell therapy, COVID-19, and inflammation. The core is not manufacturing scale; it is patent-protected medicine, payer access, clinical data, and global commercialization. Operating cash flow already reflects research and development expense, so the free cash flow that remains after capital expenditure funds dividends, buybacks, debt service, and business development.

The value stack begins with HIV. Biktarvy is the largest product and the main margin contributor, while Descovy and Sunlenca/lenacapavir extend the prevention and treatment architecture. Veklury is now a smaller, volatile COVID-related product rather than the thesis engine. Liver disease adds a mature cash layer, with Livdelzi becoming a growth offset to declining HCV products. Oncology is the intended second leg: Trodelvy is the antibody-drug conjugate proof point, Kite's Yescarta and Tecartus provide cell-therapy infrastructure, and Arcellx adds full ownership of anito-cel ahead of a potential multiple-myeloma launch.

That asset mix makes Gilead a patent-cycle IP business, not a diversified healthcare utility. Branded therapies led by antiviral small molecules and oncology biologics/cell therapies create high gross margins, but the portfolio must be continuously replaced as exclusivity, payer rebates, and clinical competition reset the economics of older products.